Nov 12, 2024 / 10:30PM GMT
Editor
Portions of this transcript marked (audio in progress) indicate audio problems. The missing text will be supplied if a replay becomes available.
Megan LeDuc - Ginkgo Bioworks Holdings Inc - Manager, Investor Relations
(audio in progress) Shift from small early-stage customers tumors, along with the change made as part of the restructuring, we supported a total of 136 active programs across 81 customers on the cell engineering platform. This represents a 17% increase in active programs each year over year.
As we discussed at our Q1 and Q2 earnings calls, the nature of programs that we take some of ours has evolved following our recent adjustments to commercial terms and the launch of our debt offering while still very early days.
This slide gives you some detail on how the nature of programs is changing. We added a total of 25 new bids and contracts in Q3 2024, of which 11 were generally comparable in size and scope just historically reported new programs and were included in the current active program count on the prior slide.
Q3 2024 Ginkgo Bioworks Holdings Inc Earnings Call Transcript
Nov 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers